Page 180 - CW E-Magazine (19-11-2024)

CPHI MILAN 2024 CPHI MILAN 2024

CPHI ANNUAL REPORT 2024 BIOLOGICS CAPACITY PREDICTIONS

Brighter outlook for US and European biotech sector; ‘Contract manufacturers and hybrid companies

boost for outsourcing activities in 2025 to hold over half of biologics capacity in 2028’

The CPHI Annual Report 2024 has Contract manufacturing organisa- CMO capacity is rising fastest and BDO, over the last two decades
forecast promising growth for biotech tions (CMOs) and ‘hybrid companies’ – will account for 40% by 2028, with overall capacity has expanded rapidly
and pharma markets in the coming those with both their own pipelines 45% of this located within Asia. This from nearly 600-kl in 2000 to just over
year, bringing growth opportunities for and contract services to utilise spare suggests that, while there will be avail- 6,700-kl today and is projected to in-
outsourcing providers. capacity – will account for over half able capacity for new clinical products crease to nearly 9,000-kl by 2028. Signi-
of global biologics capacity within entering development, it may not be fi cantly and, for the fi rst time, CMOs
The annual report, released ahead the next three years, according to the as easily accessible in the US – with will boast four of the top fi ve capa-
of the CPHI’s fl agship event in Europe, CPHI Annual Report. Europe and Asia combined accounting cities in 2028, with Lonza, Samsung,
highlights the challenges and opportuni- for around three-quarters of all avail- FujiFilm Diosynth Biotechnologies, and
ties in the global pharma industry, while This is a dramatic shift from cur- able CMO resources in 2028. WuXi Biologics controlling a massive
looking ahead to provide vital early in- rent (2024) global totals where in- 34% of capacity between them. In fact,
sights on the trends and developments house controlled capacity is presently According to the analysis by CPHI by 2028 CMOs will hold nearly 60%
that will shape the industry over the next nearly 60%, with CMOs 28%, and expert, Ms. Dawn Ecker, Managing of capacity within the top ten capacity
fi ve years. The report includes a review hybrids 15%. The report identifi es that Director, bioTRAK Database Services, holders, according to the analysis.
of the ‘Annual CPHI Survey’ of pharma
industry executives and analysis from CPHI Annual Report expert, Mr. strong commercial interest in the next REWARDING EXCELLENCE
over ten global experts who forecast the Brian Scanlan, Edgewater Capital, noted 18 months. CRO/CDMOs focused
trends of tomorrow. that the “overall cash runways are im- on therapeutic modalities like ADCs, CPHI pharma awards recognise innovations across
proving, alongside favourable economic biologics, and small molecules – rather
The latest report has indicated a conditions and interest rate cuts. This, in than cell and gene therapies – are supply chain and individual excellence
strong 2025 outlook, particularly for turn, should prompt biotechs to return to also expected to experience increased
larger CDMOs and those with US- more traditional spending patterns, with momentum through 2024 and into 2025 The ‘CPHI Excellence in Pharma
based assets or specialised technologies CRO/CDMOs benefi ting from increased as ‘safer’ bets. Award 2024’ given away at the Milan
such as peptides and radiopharmaceuti- confi dence in the fi nancial outlook over show, recognised outstanding achieve-
cals. Notably, European biotech led the the next 12 months.” Specialised CRO/CDMOs, parti- ments and contributions made within
way in 2024, securing strong venture cularly those with expertise in radio- the global pharma industry, across 14
funding compared to the past two years Funding is, however, not being dis- pharmaceuticals and peptides, are poised categories, including two new ones:
and is set to surpass all prior years, tributed evenly. While CDMOs focused for growth. The high barriers to entry in ‘Future Leader’ and ‘Woman of the
excluding 2021. In fact, even US inves- on later-stage and commercial projects these areas could create a supply-demand Year’.
tors, traditionally focused on domestic are experiencing better growth, early- imbalance as more complex radiopharma
opportunities, are increasingly turning stage biotechs and smaller CDMOs, parti- ceuticals and peptides enter clinical pipe- In the ‘Future Leader’ category, it
their attention to Europe and the UK cularly those in pre-clinical and clinical lines, according to the report. was Ms. Megan Smyth who was seen
for emerging hubs of innovation. In stages, are facing more challenges. as a rising star, reinforced by the fact
contrast, China’s venture market conti- Additionally, with IPOs remaining Despite positive trends, challenges she had risen through fi ve levels in
nues to decline, trending toward 2019 weak, companies with de-risked assets remain. The biotech sector continues to her seven years at UK-based Almac
levels and well below the peaks of 2022 are fi nding more favour with both inves- be saturated with companies competing Sciences.
and 2023. tors and pharma companies. for the same funding. Although some
consolidation has occurred, the number Ms. Julia Tsetis, CEO, OFET
Biotech venture funding has recove- In a further boost for large CD- of companies with active R&D pipe- Pharmaceutical Group, was recognised
red during the fi rst two quarters of MOs, big pharma continues to cut lines has grown throughout 2024, now as the fi rst ‘CPHI Woman of the Year’.
2024, with signifi cant improvements in R&D resources, favouring outsourcing surpassing 6,000 globally. Over 50% of She is also one of the few women
‘follow-on’ funding compared to 2022 as a medium-term solution. The grow- these companies have only one or two CEOs in Greece who was the Fortune
lows. However, IPO activity remains ing demand for GLP-1 production and products in development, making them Greece’s powerful women of the year.
sluggish, with rates well below pre- CDMOs specialising in fi ll-fi nish and less attractive in the current market to
pandemic levels. peptide manufacturing are likely to see investment. This year’s ‘CEO of the Year CPHI Award Winners

180 Chemical Weekly November 19, 2024 Chemical Weekly November 19, 2024 181

Contents Index to Advertisers Index to Products Advertised